This trial is active, not recruiting.

Condition prostatic neoplasms
Treatment leuprolide mesylate
Phase phase 3
Sponsor Foresee Pharmaceuticals Co., Ltd.
Collaborator QPS-Qualitix
Start date August 2014
End date October 2016
Trial size 130 participants
Trial identifier NCT02234115, 2013-001790-25, FP01C-13-001


The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
leuprolide mesylate
Subcutaneous injection of 50mg Leuprolide Mesylate

Primary Outcomes

Efficacy of Leuprolide Mesylate (LMIS 50mg)
time frame: 336 days

Secondary Outcomes

Post-suppression excursions of serum testosterone
time frame: 336 days
Pharmacokinetics of Leuprolide Mesylate (LMIS 50mg)
time frame: Days 0, 1, 2, 3, 7, 14, 21, 28, 56, 84, 112, 140, 168, 169, 170, 171, 196, 224, 252,280, 308, 336
Safety and tolerability of LMIS 50 mg
time frame: 336 days

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: 1. Males aged ≥ 18 years old 2. Males with histologically confirmed carcinoma of the prostate 3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy 4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit 5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2 6. Life expectancy of at least 18 months 7. Laboratory values - Absolute neutrophil count ≥ 1,500 cells/µL - Platelets ≥ 100,000 cells/µL - Hemoglobin ≥ 10 gm/dL - Total bilirubin ≤ 1.5 × upper limit of normal (ULN) - AST (SGOT) ≤ 2.5 × ULN - ALT (SGPT) ≤ 2.5 × ULN - Serum creatinine ≤ 1.5 mg/dL - Lipid profile within acceptable range according to investigator's judgment - HgbA1c within acceptable range according to investigator's judgment - Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment - Serum glucose within acceptable range according to investigator's judgement - Urinalysis within normal range according to the investigator's judgment 8. Agree to use male contraceptive methods during study trial 9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol 10. All aspects of the protocol explained and written informed consent obtained Exclusion Criteria: - Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study. - Receipt of any vaccination (including influenza) within 4 weeks of Baseline - History of blood donation within 2 months of Baseline - History of anaphylaxis to any LH-RH analogues - Receipt of any LHRH suppressive therapy within 6 months of Baseline - Major surgery, including any prostatic surgery, within 4 weeks of Baseline - History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases. Subjects at risk for spinal cord compression will be excluded. - Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction - History of bilateral orchiectomy, adrenalectomy, or hypophysectomy - History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline - Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator - History of drug and/or alcohol abuse within 6 months of Baseline - Contraindication to leuprolide or an LHRH agonist as indicated on package labeling - Use of 5-alpha reductase inhibitor within the last 6 months of Baseline - History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed - Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens - Use of any investigational agent within 4 weeks of Baseline - Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section. - Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Additional Information

Official title An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma
Description This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Foresee Pharmaceuticals Co., Ltd..